What is Allertech Laboratories?
Founded in 2012, Allertech Laboratories operates at the intersection of immunology and clinical practice management. The firm specializes in the identification, diagnosis, and long-term treatment of allergic conditions, moving beyond symptomatic relief to address underlying physiological triggers. By providing advanced testing protocols and immunotherapy solutions, Allertech enables medical practitioners to integrate comprehensive allergy services directly into their existing workflows. This dual-value proposition—improving patient outcomes while simultaneously enhancing practice revenue—has established the company as a critical partner for healthcare providers seeking to modernize their diagnostic capabilities.
How much funding has Allertech Laboratories raised?
Allertech Laboratories has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Allertech Laboratories
PPP
Public-Private Partnership
What's next for Allertech Laboratories?
With this late-stage capital, Allertech Laboratories is poised to scale its operational footprint and deepen its market penetration. The strategic focus will likely shift toward expanding its network of partner medical practices and investing in the next generation of immunotherapy research. As the company matures, the emphasis will remain on optimizing the delivery of personalized allergy care, ensuring that its diagnostic infrastructure remains at the forefront of the industry. Future growth will be defined by the company's ability to maintain its high standard of clinical efficacy while navigating the complexities of the broader healthcare landscape.
See full Allertech Laboratories company page
